Northstar Asset Management LLC reduced its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 6.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,270 shares of the medical research company’s stock after selling 2,160 shares during the quarter. Thermo Fisher Scientific accounts for about 2.8% of Northstar Asset Management LLC’s holdings, making the stock its 6th largest holding. Northstar Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $6,295,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Proficio Capital Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 71.5% in the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after purchasing an additional 253 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth about $108,000. Cribstone Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 8.7% in the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock worth $109,000 after purchasing an additional 50 shares in the last quarter. Shine Investment Advisory Services Inc. purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth about $113,000. Finally, Ropes Wealth Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 15.8% in the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after purchasing an additional 97 shares in the last quarter. Hedge funds and other institutional investors own 83.78% of the company’s stock.
Shares of Thermo Fisher Scientific Inc (NYSE:TMO) opened at $190.17 on Friday. The firm has a market capitalization of $76,257.22, a PE ratio of 20.90, a P/E/G ratio of 1.74 and a beta of 1.08. Thermo Fisher Scientific Inc has a fifty-two week low of $139.07 and a fifty-two week high of $201.20. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. Thermo Fisher Scientific’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.03 EPS. equities analysts predict that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is 10.19%.
COPYRIGHT VIOLATION WARNING: “Thermo Fisher Scientific Inc (TMO) is Northstar Asset Management LLC’s 6th Largest Position” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/11/19/thermo-fisher-scientific-inc-tmo-is-northstar-asset-management-llcs-6th-largest-position.html.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the transaction, the chief executive officer now owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Peter E. Hornstra sold 3,894 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total value of $721,090.92. Following the transaction, the vice president now directly owns 19,751 shares of the company’s stock, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. Insiders have sold a total of 60,420 shares of company stock valued at $11,308,477 in the last ninety days. 0.49% of the stock is currently owned by corporate insiders.
A number of equities analysts have recently issued reports on TMO shares. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price objective for the company in a report on Thursday, September 7th. Cowen and Company reiterated a “buy” rating and issued a $200.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, September 1st. Argus reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. BidaskClub cut Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Finally, Goldman Sachs Group, Inc. (The) started coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price objective for the company. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific has an average rating of “Buy” and an average target price of $205.71.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.